The effects of concurrent cannabis use among ecstasy users: Neuroprotective or neurotoxic?

Human Psychopharmacology

Volumn 21, Issue 6, 2006, Pages 355-366

  Fisk, Joh E ^a   Montgomery, Catharine ^b   Wareing, Michelle ^b   Murphy, Philip N ^c  

^a UNIVERSITY OF CENTRAL LANCASHIRE   (United Kingdom)

^b LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

^c EDGE HILL UNIVERSITY   (United Kingdom)

Author keywords

Cannabis; Cognitive functioning; Ecstasy

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMPHETAMINE; CANNABINOID; CANNABIS; COCAINE; NEUROPROTECTIVE AGENT;

ADULT; AGE DISTRIBUTION; ANALYTICAL ERROR; ARTICLE; BRAIN FUNCTION; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG RESEARCH; DRUG USE; EDUCATION; FEMALE; HUMAN; INTELLIGENCE; LOGIC; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL COMPUTING; NEUROPROTECTION; NEUROTOXICITY; PRIORITY JOURNAL; READING; STATE DEPENDENT LEARNING; VERBAL MEMORY; WORKING MEMORY;

AGE FACTORS; AGING; COGNITION; DRUG INTERACTIONS; EDUCATIONAL STATUS; FEMALE; HALLUCINOGENS; HUMANS; INTELLIGENCE; LEARNING; MALE; MARIJUANA SMOKING; MEMORY; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PROBLEM SOLVING; REACTION TIME; SPACE PERCEPTION; VISUAL PERCEPTION;

EID: 33748511026     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.777     Document Type: Article

References (47)

1. Azad SC, Marsicano G, Eberlein I, et al. 2001. Differential role of the nitric oxide pathway on d-9-tetrahydro-cannabinol induced central nervous system effects in the mouse. Eur J Neurosci 13(3): 561-568.
2. Carter GT, Weydt P, Kyashna-Tocha M, Abrams DI. 2004. Medicinal cannabis: rational guidelines for dosing. Idrugs 7: 464-470.
3. Croxford JL. 2003. Therapeutic potential of cannabinoids in CNS desease. CNS Drugs 17: 179-202.
4. Curran HV. 2000. Is MDMA ('ecstasy') neurotoxic in humans? An overview of evidence and of methodological problems in research. Neuropsychobiology 42: 34-41.
5. Doble A. 1999. The role of excitotoxicity in neurodegenerative disease: implications for therapy. Pharmacol Ther 81: 163-221.
6. Drysdale AJ, Platt B. 2003. Cannabinoids: mechanisms and therapeutic applications in the CNS. Curr Med Chem 10: 2719-2732.
7. Fehr KA, Kalant H, Leblanc AE. 1976. Residual learning deficit after heavy exposure to cannabis or alcohol in rats. Science 192(4245): 1249-1251.
8. Fisk JE. 2004. The relative magnitudes of age related deficits in verbal and visuo-spatial working memory. Proc Br Psychol Soc 12: 169.
9. Fisk JE, Montgomery C, Murphy P, Wareing M. 2004. Evidence of executive deficits among users of MDMA (Ecstasy). Br J Psychol 95: 457-466.
10. Fisk JE, Montgomery C, Wareing M, Murphy P. 2005. Reasoning deficits in ecstasy (MDMA) polydrug users. Psychopharmacology 181: 550-559.
11. Fisk JE, Sharp C. 2002. Syllogistic reasoning and cognitive ageing. Q J Exp Psychol 55A: 1273-1293.
12. Fisk JE, Warr P. 1996. Age and working memory: the role of perceptual speed, the central executive and the phonological loop. Psychol Aging 11: 316-323.
13. Fox HC, McLean A, Turner JJD, Parrott AC, Rogers R, Sahakian BJ. 2002. Neuropsychological evidence of a relatively selective profile of temporal dysfunction in drug-free MDMA ("ecstasy") polydrug users. Psychopharmacology 162: 203-214.
14. Gonzalez R, Rippeth JD, Carey CL, et al. 2004. Neurocognitive performance of methamphetamine users discordant for history of marijuana exposure. Drug Alcohol Depend 76: 181-190.
15. Grundy RI. 2002. The therapeutic potential of the cannabinoids in neuroprotection. Expert Opin Invest Drugs 11: 1365-1374.
16. Guzman M, Sanchez C, Galve-Roperth I. 2001. Control of cell survival/ death decision by cannabinoids. J Mol Med-JMM 78: 613-626.
17. Hall W, Solowij N. 1998. Adverse affects of cannabis. Lancet 352: 1611-1616.
18. Hubert JP, Doble A. 1998. Neuroprotective compounds inhibit depoloarisation-evoked calcium transients in granule cells. Drug Dev Res 45: 74-82.
19. Johnson-Laird PN. 1983. Mental Models. Cambridge University Press: Cambridge, UK.
20. Lawston J, Borella A, Robinson JK, et al. 2000. Changes in hippocampal morphology following chronic treatment with the synthetic cannabinoid WIN 55,212-2. Brain Res 877: 407-410.
21. Malberg JE, Sabol KE, Seiden LS. 1996. Co-administration of MDMA with drugs that protect against MDMA neurotoxicity produces different effects on body temperature in the rat. J Pharmacol Exp Ther 278: 258-267.
22. Malberg JE, Seiden LS. 1998. Small changes in ambient temperature cause large changes in 3,4-methylenedioxymethamphetamine (MDMA) induced serotonin neurotoxicity and core body temperature in the rat. J Neurosci 18(3): 5086-5094.
23. McCann UD, Szabo Z, Scheffel U, Dannals RF, Ricaurte GA. 1998. Positron emission tomographic evidence of toxic effect of MDMA ("ecstasy") on brain serotonin neurons in human beings. The Lancet 352: 1433-1437.
24. Miyake A, Friedman NP, Rettinger DA, Shah P, Hegarty M. 2001. How are visuospatial working memory, executive functioning, and spatial abilities related? A latent variable analysis. J Exp Psychol Gen 130: 621-640.
25. Montgomery C, Fisk JE, Newcombe R. 2005a. The nature of ecstasy-group related deficits in associative learning. Psychopharmacology 180: 141-149.
26. Montgomery C, Fisk JE, Newcombe R, Murphy P. 2005b. The differential effects of ecstasy/polydrug use on executive components: shifting, inhibition, updating and access to semantic memory. Psychopharmacology 182: 262-276.
27. Montgomery C, Fisk JE, Newcombe R, Wareing M, Murphy P. 2005c. Syllogistic reasoning performance in MDMA (Ecstasy) users. Exp Clin Psychopharmacol 13: 137-145.
28. Morgan MJ. 1998. Recreational use of "ecstasy" (MDMA) is associated with elevated impulsivity. Neuropsychopharmacology 19: 252-264.
29. Morgan MJ. 1999. Memory deficits associated with recreational use of "ecstasy" (MDMA). Psychopharmacology 141: 30-36.
30. Morgan MJ. 2000. Ecstasy (MDMA): a review of its possible persistent psychological effects. Psychopharmacology 152: 230-248.
31. Parrott AC, Lasky J. 1998. Ecstasy (MDMA) effects upon mood and cognition: before, during and after a saturday night dance. Psychopharmacology 139: 261-268.
32. Pope HG, Gruber AJ, Hudson JI, Huestis MA, Yurgelun-Todd D. 2001. Neuropsychological performance in long term cannabis users. Arch Gen Psychiatry 58: 909-915.
33. Pope HG, Yurgelun-Todd D. 1996. The residual cognitive effects of heavy marijuana use in college students. JAMA 275: 521-527.
34. Raven J, Raven JC, Court JH. 1998. Manual for Raven's Progressive Matrices and Vocabulary Scales. Oxford Psychologists Press: Oxford UK.
35. Rawls SM, Cowan A, Tallarida RJ, Geller EB, Adler MW. 2002. N-methyl-d-aspartate antagonists and WIN55212-2 [4,5dihydro-2-methyl-4 (4-morpholinylmethyl)-1-(1-naphthalenyl-carbonyl)-6H-pyrrolo [3,2,1,I,j] quinolin-6-one], a cannabinoid agonist interact to produce synergistic hypothermia. J Pharmacol Exp Ther 303(1): 395-402.
36. Reneman L, Endert E, de-Bruin K, et al. 2002b. The acute and chronic effects of MDMA ("Ecstasy") on cortical 5-HTsub(2A) receptors in rat and human brain. Neuropsychopharmacology 26: 387-396.
37. Reneman L, Majoie CBLM, Flick H, den Heeten GJ. 2002a. Reduced N-acetylaspartate levels in the frontal cortex of 3,4-methylenedioxymethampetamine (ecstasy) users: preliminary results. Am J Neuroradiol 23: 231-237.
38. Reneman L, de Win MML, van den Brink W, Booij J, den Heeten GJ. 2006. Neuroimaging findings with MDMA/ecstasy: technical aspects, conceptual issues and future prospects. J Psychopharmacol 20: 164-175.
39. Rodgers J. 2000. Cognitive performance amongst recreational users of "ecstasy". Psychopharmacology 151: 19-24.
40. Rubovitch V, Gafni M, Sarne Y. 2002. The cannabinoid agonist DALN positively modulates L-type voltage-dependent calcium-channels in N18TG2 neuroblastoma cells. Mol Brain Res 101(1-2): 93-102.
41. Sarne Y, Keren O. 2004. Are cannabinoid drugs neurotoxic or neuroprotective? Med Hypotheses 63: 187-192.
42. Sarne Y, Tselnicker B, Pick C, Keren O. 2005. Dissociating between neuroprotective and neurotoxic effects of THC (delta-9 tetrahydrocannabinol). Paper presented at the International Association for Cannabis as Medicine (IACM) 3rd Conference on Cannabinoids in Medicine, Leiden University, 9-10th September, 2005.
43. Solowij N, Hall W, Lee N. 1992. Recreational MDMA use in Sydney: a profile of ecstasy users and their experiences with the drug. Br J Addict 87: 1161-1172.
44. Wareing M. 2005. Working Memory and Executive Deficits Among MDMA ('Ecstasy') Users. Unpublished PhD Thesis.
45. Wareing M, Fisk JE, Murphy P. 2002. Little evidence for central executive impairment among light/moderate users of MDMA. Proc Br Psychol Soc 10: 107.
46. Wareing M, Fisk JE, Murphy P, Montgomery C. 2004. Verbal working memory deficits in current and previous users of MDMA. Hum Psychopharmacol Clin Exp 19: 225-234.
47. Wareing M, Fisk JE, Murphy P, Montgomery C. 2005. Visuo-spatial working memory deficits in current and former users of MDMA ('Ecstasy'). Hum Psychopharmacol Clin Exp 20: 115-123.